Summary.-Experiments are described in which dose-response data have been obtained for EMT6 mouse tumour cells growing in vivo and exposed to various cytotoxic agents. A comparison has been made of the response of solid tumours in the flank and of rapidly growing lung nodules. The results are discussed with regard to their cell kinetic implications and compared with our results for the chemosensitivity of EMT6 cells in exponential and plateau phase growth in vitro.
THERE have been several recent studies in, which various groups of workers have compared the sensitivity to cytotoxic drugs of mammalian cells during the exponential and plateau phases of growth. (Barranco, Novak and Humphrey, 1973 ; Barranco and Novak, 1974; Twentyman and Bleehen, 1975a, b; Hahn, Gordon and Kurkjian, 1974; . The interest in this type of study has been based on the fact that certain similarities exist between the cell proliferation kinetics of plateau phase cultures and the kinetics of experimental solid tumours (Hahn and Little, 1972 We have therefore carried out experiments to compare the sensitivity to cytotoxic drugs in vivo of the EMT6 cell line either during rapid exponential growth in the lungs (Brown, 1974) or else growing more slowly as a solid flank tumour. The results of these studies are reported in this paper.
MATERIALS AND METHODS
The EMT6 cell line may be grown either in vivo as a solid tumour or in vitro as a monolayer (Rockwell, Kallman and Fajardo, 1972) . In addition, assay of cell survival following treatment in vivo may be carried out by in vitro plating. The particular subline of the tumour used in these experiments was designated EMT6/VJ/AC and was originally supplied to us by Dr E. Frindel. The line is maintained by alternating growth as a solid tumour in vivo, and four passages in vitro.
For experiments, male Balb/C mice between 10 and 14 weeks of age were inoculated with cells taken from the second, third and fourth in vitro passage since removal from a previous in vivo passage. For solid flank tumours, 4 x 104 cells were inoculated intradermally in a volume of 0 05 ml of complete culture medium. For growth as lung nodules, 105 cells were injected into the lateral tail vein in a volume of 0-25 ml of Hanks' solution. The growth of solid tumours was monitored using calipers. Three diameters, mutually at right angles, were measured, and the tumour volume was Preparation of a single cell suspension from solid tumours and in vitro assay for surviving fraction wvas carried out as previously described Bleehen, 1974, 1975c) . For lung nodules, the method was virtually identical except that for each complete set of lungs a volume of 15 ml of trypsinized Hanks' solution was used because of the greater mass of tissue involved.
In order to obtain the growth curve for lung nodules, lungs were removed from mice at various times after inoculation of 105 cells and various proportions of each set of lungs were plated out. From the number of colonies produced in vitro, it was possible to obtain a value for " dish colonies/set of lungs ". (Twentyman and Bleehen, 1974) that for the EMT6 solid tumour over a wide range of sizes, the 2 h doseresponse curve has virtually reached a plateau of survival at 1 mg/kg and that this plateau continues until at least 10 mg/kg. Furthermore, we have also shown that tumours of all sizes appear to " repair potentially lethal damage " if assay is delayed until 24 h following drug administration. More recently, we have shown that the measured surviving fraction is at a minimum about 30 min after BLM administration and that " repair " is virtually complete by 6 h (Twentyman and Bleehen, 1975c We have discussed this effect fully in a recent publication (Twentyman and Bleehen, 1975c) . What is very obvious from the results, however, is that this effect operates to nearly the same extent in lung nodules as it does in the solid tumour. If, therefore, this effect of delayed subculture in vivo operates via the same mechanism as that in vitro, our finding would agree wvith the observation that the ability to repair potentially lethal damage is possessed by both exponential and plateau phase cells in vitro (Barranco et al., 1975; Twentymain and Bleehen, 1975c) rather than being confined to plateau phase cells (Ray et al., 1973) . The results reported here are consistent with our observation (Twentyman and Bleehen, 1973 ) that proliferating spleen colony-forming cells in mouse marrow are more sensitive than are quiescent CFUs to BLM when assay is carried out at 24 h after drupg administration, although it is possible that a different conclusion may have been reached had the assay been performed at a different time.
Adriamnycin. Our previously reported results for the response of exponential and plateau phase cells in vitro to ADM (Twentyman and Bleehen, 1 975b) are similar to those reported by Barranco a(ndl Novak (1974) . The response for exponential phase cells is very rapid, fallfing to 10-3 for a dose of 1 pg/ml for 1 h, whereas the response of plateau phase cells is very much less, the surviving fraction being in excess of 10-1 at 1 /ig/ml.
If these in vitro r-esults could be directly applied to the in vivo situation, then one wotuld expect the dose-response curves for lung nodules aind solid tumours to be very different. In fact, both systems are extremely insensitive to even very hiigh doses of this agent. This could, of course, be due to the druig not reaching the cells wheni given by the i.p. route. However, Hahn, Brauii and Har-Kedar (1975) of the total population. Also, in a study of the P815X2 mastocytoma in the mouse, the tumour cells were found by Hagemann, Schenken and Lesher (1973) to be very resistant to BCNU, and the authors suggest that drug availability is the likely cause.
Otur data for lung nodules suggest a response curve which is perhaps a little steeper than that for the solid tumour. It would appear therefore, that in our solid tumour system, there is no large populatioin of cells which is resistant to BCNU for ainy reason. Furthermore, the sensitivity of the cycling and noncycling compartment appears to be similar. This is in agreement with our findings that EMT6 cells growing in vitro show similar sensitivity to BCNU in the exponiential, early plateau and late plateau phases of growth (Twentyman and Bleehen, 1975b) . The data for other tumours, however, indicate that our findings may not apply to all such systems.
CCONU. Absence of repair of potentially lethal da,mage observed for CCNU in our system is in agreement wvith the findings in vitro of Barraanco et al. (1975) . Again, the sensitivity of EMT6 cells in solid tumours and in lung nodules appears to be similar with no evidence for the presence of a resistant fraction in the solid tumour. This result is in agreement with that of Hill and Stanley (1975) for the B16 melanoma, and also with our in vitro results for EMT6 cells in exponential aand plateau phase (Twentyman and Bleehen, 1975b) .
In general, therefore, in our system there does not seem to be much difference in the response of lung nodules and solid tumours to any of the agents studied. This is in contrast to the results of Conzelman and Springer (1969) who found that the SAHi -1 mouse tumour was more sensitive to several drugs when growing subcutaneously than when growing in the lungs.
The results presented in the present paper, notably those for ADM, further emphasize a point we have made in previous publications, i.e. it is dangerous to extrapolate results obtained in one experimental situation to another situation. This applies both to extrapolation from one cell line to another in vitro and to extrapolation from the in vitro to the in vivo situation for the same cell line. Before such comparisons caIn legitimately be made, we need to know much more about the factors both kinetic and otherwise which determine the response of cells to cytotoxic drugs.
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